Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.

Carbohydrate polymers - 15 Aug 2026

Zaiki Yazid, Chee Chin Fei, Ageitos Lucia, Naharudin Idanawati, Zainudin Badrul Hisyam, Leong Lek Mun, Jaime Rodriguez González, Jimenez Carlos, Gan Chee Yuen, Traini Daniela, Wong Tin Wui

Abstract excerpt

Cell targeting/permeabilization, organelle/biochemical pathway regulation, and drug resistance/metastasis/immunological expressions are considerations to advance cancer nanomedicine design. This study modulated mitochondria-targeting YKWYYRGAA (P1) peptide, into a multifunctional excipient via N-methylation and N-dimethylation, to synergise nano-chitosan conjugate in drug delivery and non-small cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chitosan

Share to Drug Carriers

Share to GTP Phosphohydrolases

Share to Mitochondria

Share to Nanoparticles

Source

Identifiers

PMID: 42230031
DOI: 10.1016/j.carbpol.2026.125423

Genes

EGFR
NRAS
GSTP1
MICA
MMP9
ULBP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.PMID 42230031Read ↗

Targeted delivery of metastasis-specific tumour homing TMTP1 peptide to non-small-cell lung cancer (NSCLC) using inhalable hybrid Nano-assembliesSemantic proximity Read ↗

Nanomedicine Strategies for Management of Drug Resistance in Lung CancerSemantic proximity Read ↗

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity Read ↗

Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages.Semantic proximity Read ↗

Nanomedicine Strategies to Overcome Multi-Drug Resistance in Cancer: Innovations in Targeted Delivery, Tumor Microenvironment Modulation and Synergistic TherapiesSemantic proximity Read ↗

Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer.Semantic proximity Read ↗

Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy.Semantic proximity Read ↗

Nanoparticle-based drug delivery systems: What can they really do in vivo?Semantic proximity Read ↗

A super-assembled synergistically nanoplatform AP@ZIF-8 Pt for hepatocarcinoma therapySemantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Bioactive Co-assembly of PSA/dit-VES Nanomicelles Orchestrates Macrophage Reprogramming for Acute Lung Injury TherapySemantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.